Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O6ZO
|
|||
| Former ID |
DIB006571
|
|||
| Drug Name |
TAK-715
|
|||
| Synonyms |
P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | |
| Company |
Takeda Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H21N3OS
|
|||
| Canonical SMILES |
CCC1=NC(=C(S1)C2=CC(=NC=C2)NC(=O)C3=CC=CC=C3)C4=CC=CC(=C4)C
|
|||
| InChI |
1S/C24H21N3OS/c1-3-21-27-22(18-11-7-8-16(2)14-18)23(29-21)19-12-13-25-20(15-19)26-24(28)17-9-5-4-6-10-17/h4-15H,3H2,1-2H3,(H,25,26,28)
|
|||
| InChIKey |
HEKAIDKUDLCBRU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 303162-79-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:91360
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Stress-activated protein kinase (p38) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00760864) Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | |||
| REF 2 | Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.